Pharmaceuticals

Latest KFF Health News Stories

KHN’s ‘What the Health?’: Medicaid Machinations

KFF Health News Original

The lame-duck Congress has returned to Washington with a long health care to-do list and only a little time. Meanwhile, some of the states that have not yet expanded Medicaid eligibility under the Affordable Care Act are rethinking those decisions. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these topics and more. Also this week, Rovner interviews KHN’s Fred Clasen-Kelly, who reported and wrote the latest KHN-NPR “Bill of the Month” feature, about a mysterious mishap during minor surgery.

Defense Department Health Plan Cuts Its Pharmacy Network by Nearly 15,000 Outlets

KFF Health News Original

Many of the pharmacies were small, independent operations that had decided not to participate next year because of the lowered reimbursement being offered. But they were surprised by an early dismissal, and some patients with specialized drug needs could face difficulties in the transition.

$38,398 for a Single Shot of a Very Old Cancer Drug

KFF Health News Original

Lupron, a drug patented half a century ago, treats advanced prostate cancer. It’s sold to physicians for $260 in the U.K. and administered at no charge. Why are U.S. hospitals — which may pay nearly as little for the drug — charging so much more to administer it?

KHN’s ‘What the Health?’: Biden Hits the Road to Sell Democrats’ Record

KFF Health News Original

With the midterm elections rapidly approaching, President Joe Biden has taken to the road to convince voters that he and congressional Democrats have delivered for them during two years in power. Among the health issues highlighted by the administration this week are pandemic preparedness and the availability of over-the-counter hearing aids. The president also promised to sign a bill codifying the abortion protections of Roe v. Wade if Democrats maintain control of the House and Senate — even though it’s a long shot that there will be enough votes for that. Sarah Karlin-Smith of the Pink Sheet, Sandhya Raman of CQ Roll Call, and Mary Agnes Carey of KHN join KHN’s Julie Rovner to discuss these topics and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.

El vínculo con la esclerosis múltiple impulsa una vacuna contra el virus Epstein-Barr

KFF Health News Original

Los científicos llevan años intentando desarrollar vacunas contra este virus. Sin embargo, recientemente varios avances en la investigación médica han dado más urgencia a la búsqueda y más esperanzas de éxito.

As Links to MS Deepen, Researchers Accelerate Efforts to Develop an Epstein-Barr Vaccine

KFF Health News Original

Recent leaps in medical research have lent urgency to the quest to develop a vaccine against Epstein-Barr, a ubiquitous virus that has been linked to a range of illnesses, from mononucleosis to multiple sclerosis and several cancers.

La nueva generación de medicamentos para la pérdida de peso es prometedora, pero tiene un precio

KFF Health News Original

Algunos pacientes, según los especialistas en medicina de la obesidad, experimentan una disminución de la presión arterial, un mejor control de la diabetes, menos dolor en las articulaciones y un mejor sueño gracias a estos nuevos tratamientos.

New Generation of Weight Loss Medications Offer Promise — But at a Price

KFF Health News Original

People now have at their disposal more medicines that are effective at reducing weight, but none can counter obesity alone. One big problem: Insurance coverage remains spotty, and the costly drugs may be needed long term.

KHN’s ‘What the Health?’: On Government Spending, Congress Decides Not to Decide

KFF Health News Original

Congress has once again decided not to decide how to fund the federal government in time for the start of the fiscal year, racing toward a midnight Sept. 30 deadline to pass a stopgap bill that would keep the lights on for two more months. However, it does appear the FDA’s program that gets drugmakers to help fund some of the agency’s review staff will be renewed in time to stop pink slips from being sent. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Victoria Knight of Axios join KHN’s Julie Rovner to discuss these topics and more. Also this week, Rovner interviews filmmaker Cynthia Lowen, whose new documentary, “Battleground,” explores how anti-abortion forces played the long game to overturn Roe v. Wade.

Médicos se apresuran a usar fallo de la Corte Suprema para liberarse de cargos por opioides

KFF Health News Original

En una decisión de junio, el tribunal dijo que los fiscales no solo deben probar que una receta no estaba médicamente justificada sino también que el que la escribió sabía del riesgo de recetar opioides.

Court Ruling May Spur Competitive Health Plans to Bring Back Copays for Preventive Services

KFF Health News Original

The Affordable Care Act required that health insurers provide many medical screenings and prevention services at no out-of-pocket cost to health plan members. But insurers and employers may consider adding cost sharing for preventive services now that a federal court ruled the ACA’s mandate is unconstitutional.